The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
 
Douglas Adkins
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Coherus Biosciences; CUE Biopharma; Eisai Europe; Exelixis; Immunitas; Kura Oncology; Merck; TargImmune Therapeutics; twoXAR; Vaccinex; Xilio Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Exelixis (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Rubius Therapeutics (Inst); Sensei Biotherapeutics (Inst); Shanghai Denovo (Inst); Vaccinex (Inst)
 
Valerii Cheshuk
No Relationships to Disclose
 
Julio Antonio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Oncology Consultants; Roche; Spectrum Pharmaceuticals; Tersera; zogen
Honoraria - Agendia; Guardant Health; Tempus
Consulting or Advisory Role - Tersera
Speakers' Bureau - Agendia; Guardant Health; Tempus
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Genentech/Roche (Inst); Immatics (Inst); ImmunityBio (Inst); Immutep (Inst); IncMed (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); NovoCure (Inst); Sermonix Pharmaceuticals (Inst); Tersera (Inst); Thrive Earlier Detection Corp (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Agendia; Guardant Health; Tempus
 
John J. Park
No Relationships to Disclose
 
Antonio Lopez-Pousa
No Relationships to Disclose
 
Willem Lybaert
No Relationships to Disclose
 
Irene Brana
Consulting or Advisory Role - Achilles Therapeutics; Cancer Expert Now; eTheRNA Immunotherapies; Merck Sharp & Dohme; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); VCN Biosciences (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Bernard Doger
No Relationships to Disclose
 
Frederic Triebel
Employment - Immutep
Stock and Other Ownership Interests - Immutep
Patents, Royalties, Other Intellectual Property - Being an inventor on patents on LAG-3 owned by Immutep SAS